Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

2.

Impact of Delayed Therapy in Serious Bacterial Infections: Role of Technology and the Clinician at the Bedside.

Levine MT, Levine DP.

Am J Med Sci. 2019 Mar;357(3):177-178. doi: 10.1016/j.amjms.2019.01.001. Epub 2019 Jan 9. No abstract available.

PMID:
30797500
3.

Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting.

Claeys KC, Zasowski EJ, Lagnf AM, Sabagha N, Levine DP, Davis SL, Rybak MJ.

Infect Dis Ther. 2018 Dec;7(4):495-507. doi: 10.1007/s40121-018-0212-3. Epub 2018 Sep 22.

4.

Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections.

Trinh TD, Zasowski EJ, Claeys KC, Casapao AM, Compton M, Lagnf A, Kidambi SD, Levine DP, Rybak MJ.

Infect Dis Ther. 2018 Mar;7(1):161-169. doi: 10.1007/s40121-018-0187-0. Epub 2018 Feb 22.

5.

Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections.

Claeys KC, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ.

Int J Antimicrob Agents. 2018 Jan;51(1):43-46. doi: 10.1016/j.ijantimicag.2017.05.015. Epub 2017 Jun 28.

PMID:
28668679
6.

Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Claeys KC, Zasowski EJ, Casapao AM, Lagnf AM, Nagel JL, Nguyen CT, Hallesy JA, Compton MT, Kaye KS, Levine DP, Davis SL, Rybak MJ.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8. doi: 10.1128/AAC.00227-16. Print 2016 Oct.

7.

Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.

Henson KE, Levine MT, Wong EA, Levine DP.

Expert Rev Anti Infect Ther. 2015;13(10):1265-78. doi: 10.1586/14787210.2015.1068118. Epub 2015 Jul 12. Review.

PMID:
26165756
8.

Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ.

Antimicrob Agents Chemother. 2015;59(6):2978-85. doi: 10.1128/AAC.03970-14. Epub 2015 Mar 9.

9.

Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.

Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, Levine DP, Rybak MJ.

Antimicrob Agents Chemother. 2014 Aug;58(8):4636-41. doi: 10.1128/AAC.02820-13. Epub 2014 Jun 2.

10.

A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.

Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

J Antimicrob Chemother. 2013 Dec;68(12):2921-6. doi: 10.1093/jac/dkt294. Epub 2013 Aug 8.

11.

Is an aminoglycoside still required for the treatment of enterococcal endocarditis?

Levine DP.

Curr Infect Dis Rep. 2013 Oct;15(5):353-5. doi: 10.1007/s11908-013-0355-z. No abstract available.

PMID:
23893051
12.

Multicenter study of high-dose daptomycin for treatment of enterococcal infections.

Casapao AM, Kullar R, Davis SL, Levine DP, Zhao JJ, Potoski BA, Goff DA, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

Antimicrob Agents Chemother. 2013 Sep;57(9):4190-6. doi: 10.1128/AAC.00526-13. Epub 2013 Jun 17.

13.

Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Kullar R, Davis SL, Kaye KS, Levine DP, Pogue JM, Rybak MJ.

Pharmacotherapy. 2013 Jan;33(1):3-10. doi: 10.1002/phar.1220.

PMID:
23307539
14.

Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.

Casapao AM, Steed ME, Levine DP, Rybak MJ.

Expert Opin Pharmacother. 2012 Jun;13(8):1177-86. doi: 10.1517/14656566.2012.685718. Review.

PMID:
22594846
15.

High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.

Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.

Pharmacotherapy. 2011 Jun;31(6):527-36. doi: 10.1592/phco.31.6.527.

PMID:
21923436
16.

MRSA guidelines: a matter of time.

Levine DP, Lanfranco OA.

Expert Rev Anti Infect Ther. 2011 May;9(5):495-6. doi: 10.1586/eri.11.36. No abstract available.

PMID:
21609259
17.

Synergy: a cautionary tale.

Levine DP.

Curr Infect Dis Rep. 2011 Aug;13(4):303-4. doi: 10.1007/s11908-011-0185-9. No abstract available.

PMID:
21491192
18.

Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets.

Kullar R, Davis SL, Levine DP, Rybak MJ.

Clin Infect Dis. 2011 Apr 15;52(8):975-81. doi: 10.1093/cid/cir124.

PMID:
21460309
19.

Clinical trial report: is it safe to continue anticoagulation therapy in patients with infective endocarditis?

Levine DP.

Curr Infect Dis Rep. 2010 Jul;12(4):231-3. doi: 10.1007/s11908-010-0109-0. No abstract available.

PMID:
21308535
20.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF.

Clin Infect Dis. 2011 Feb 1;52(3):285-92. doi: 10.1093/cid/cir034.

PMID:
21217178
21.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America.

Clin Infect Dis. 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4. Erratum in: Clin Infect Dis. 2011 Aug 1;53(3):319.

PMID:
21208910
22.

Daptomycin: pharmacology and clinical use.

Kosmidis C, Levine DP.

Expert Opin Pharmacother. 2010 Mar;11(4):615-25. doi: 10.1517/14656561003598893. Review.

PMID:
20163272
23.

Outcome of patients with injection drug use-associated endocarditis admitted to an intensive care unit.

Saydain G, Singh J, Dalal B, Yoo W, Levine DP.

J Crit Care. 2010 Jun;25(2):248-53. doi: 10.1016/j.jcrc.2009.09.007. Epub 2009 Nov 11.

PMID:
19906509
24.
25.

Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis.

Kanafani ZA, Kourany WM, Fowler VG Jr, Levine DP, Vigliani GA, Campion M, Katz DE, Corey GR, Boucher HW.

Eur J Clin Microbiol Infect Dis. 2009 Dec;28(12):1477-82. doi: 10.1007/s10096-009-0808-3.

PMID:
19730900
26.

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP.

Clin Infect Dis. 2009 Aug 1;49(3):325-7. doi: 10.1086/600877. Erratum in: Clin Infect Dis. 2009 Nov 1;49(9):1465.

PMID:
19569969
27.

Prevention of catheter-related infection: evidence-based medicine.

Levine DP.

Curr Infect Dis Rep. 2009 Jul;11(4):255-6. No abstract available.

PMID:
19545492
28.

Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.

Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW.

Clin Infect Dis. 2009 Mar 15;48(6):713-21. doi: 10.1086/597031.

PMID:
19207079
29.
30.

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP.

Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434. Review. No abstract available. Erratum in: Am J Health Syst Pharm. 2009 May 15;66(10):887.

PMID:
19106348
31.

Clinical experience with daptomycin: bacteraemia and endocarditis.

Levine DP.

J Antimicrob Chemother. 2008 Nov;62 Suppl 3:iii35-39. doi: 10.1093/jac/dkn369. Review.

PMID:
18829724
32.

Vancomycin: understanding its past and preserving its future.

Levine DP.

South Med J. 2008 Mar;101(3):284-91. doi: 10.1097/SMJ.0b013e3181647037. Review.

PMID:
18364659
33.

Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis.

Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich F, Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P, Gordon DL, Utili R, Delahaye F, Corey GR, Fowler VG Jr; International Collaboration on Endocarditis-Prospective Cohort Study Group.

Clin Infect Dis. 2008 Jan 15;46(2):232-42. doi: 10.1086/524666.

PMID:
18171255
34.

Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia.

Lalani T, Boucher HW, Cosgrove SE, Fowler VG, Kanafani ZA, Vigliani GA, Campion M, Abrutyn E, Levine DP, Price CS, Rehm SJ, Corey GR, Karchmer AW; S. aureus Endocarditis and Bacteraemia Study Group.

J Antimicrob Chemother. 2008 Jan;61(1):177-82. Epub 2007 Nov 13.

PMID:
17999973
35.

Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.

Levine DP, Lamp KC.

Am J Med. 2007 Oct;120(10 Suppl 1):S28-33.

PMID:
17904948
36.

Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia.

Rupp ME, Holley HP Jr, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG Jr.

Antimicrob Agents Chemother. 2007 Dec;51(12):4249-54. Epub 2007 Sep 24.

37.

Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ.

Antimicrob Agents Chemother. 2007 Oct;51(10):3731-3. Epub 2007 Jul 30.

38.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fätkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group.

N Engl J Med. 2006 Aug 17;355(7):653-65.

39.

Vancomycin: a history.

Levine DP.

Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12.

PMID:
16323120
40.

Staphylococcus aureus endocarditis: a consequence of medical progress.

Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS; ICE Investigators.

JAMA. 2005 Jun 22;293(24):3012-21. Erratum in: JAMA. 2005 Aug 24;294(8):900.

PMID:
15972563
41.

Clinafloxacin for the treatment of bacterial endocarditis.

Levine DP, Holley HP, Eiseman I, Willcox P, Tack K.

Clin Infect Dis. 2004 Mar 1;38(5):620-31. Epub 2004 Feb 17.

PMID:
14986244
42.

Infective endocarditis in the injection drug user.

Brown PD, Levine DP.

Infect Dis Clin North Am. 2002 Sep;16(3):645-65, viii-ix. Review.

PMID:
12371120
43.

Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review.

Tam VH, Mckinnon PS, Levine DP, Brandel SM, Rybak MJ.

Pharmacotherapy. 2000 Sep;20(9):1116-9.

PMID:
10999505
44.

Hallucinations in an elderly patient taking recommended doses of cyclobenzaprine.

Douglass MA, Levine DP.

Arch Intern Med. 2000 May 8;160(9):1373. No abstract available.

PMID:
10809044
45.

Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital.

Weingarten CM, Rybak MJ, Jahns BE, Stevenson JG, Brown WJ, Levine DP.

Pharmacotherapy. 1999 Sep;19(9):1080-5.

PMID:
10610015
46.

Editorial response: Community-acquired methicillin-resistant Staphylococcus aureus infections--where do we go from here?

Kak V, Levine DP.

Clin Infect Dis. 1999 Oct;29(4):801-2. No abstract available.

PMID:
10589892
47.

A pharmacist-initiated program of intravenous to oral antibiotic conversion.

Przybylski KG, Rybak MJ, Martin PR, Weingarten CM, Zaran FK, Stevenson JG, Levine DP.

Pharmacotherapy. 1997 Mar-Apr;17(2):271-6.

PMID:
9085318
48.
49.

Delayed detection of an increase in resistant Acinetobacter at a Detroit hospital.

Johnson DR, Love-Dixon MA, Brown WJ, Levine DP, Downes FP, Hall WN.

Infect Control Hosp Epidemiol. 1992 Jul;13(7):394-8.

PMID:
1640096
50.

Supplemental Content

Loading ...
Support Center